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Should China Provide Intellectual

Property Protection for Genetically
Modified Animals?
Ke Geng*
I. INTRODUCTION

The advent of recombinant genetic engineering techniques has revolutionized biotechnology. The biomedicine and biotechnology industries
have extensively employed these techniques to improve the quality of agricultural crops and livestock and to create genetically modified organisms
("GMOs") in order to produce drugs. Since as much as twenty-five percent
of the world's intellectual property-related trade involves biotechnology,
many countries have realized the importance of providing intellectual property protection for biotechnological technologies, including GMOs)
In the past decade, China's booming economy has helped make its biotechnological market the fastest growing market in the world. To stimulate
innovation and attract private investment in its biotechnology industry,
China has rapidly transformed its intellectual property laws to conform with
western models in the last two decades. However, plants and animals are
not patentable in China. While plant varieties enjoy sui generis system protection, animal varieties are not protected by any law. This poses a serious
problem for biotechnology firms that have heavily invested in the research
and development of genetically modified animals.
This article focuses on whether China should provide intellectual property protection for new animal varieties, including genetically modified
animals. Section II offers a brief introduction to the development of recombinant genetic engineering techniques. Section III discusses the benefits and risks of GMOs. The ethical issues of animal patenting are
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discussed in section IV. Sections V and VI present an overview of international and China's intellectual property protection for GMOs, respectively.
Section VII concludes with a discussion of why and how China should provide intellectual property protection for genetically engineered animals.
II. THE DEVELOPMENT OF RECOMBINANT GENETIC ENGINEERING
TECHNIQUES

The genetic material of living organisms has long been manipulated to
produce desired characteristics in new organisms. Plant and animal breeders have employed intraspecies crossings and selections for desirable characteristics and eventual stabilization of the new traits for centuries.' Since
the discovery that deoxyribonucleic acid (DNA) is the genetic material
which encodes all biological information, scientists have used induced
mutagenesis to modify DNA and select desirable traits.3 This new method
accelerates the conventional breeding process that may normally take generations unaided.4 However, both approaches present the same challenge:
the selection process can be extremely painful and fruitless because the
modification of DNA is random and the outcome is unpredictable.
Recombinant genetic techniques employed during the past three decades have revolutionized biotechnology. The creation of a transgenic organism involves the introduction of a foreign gene into the organism. A
living organism may generally be genetically transformed after four steps:
(1) a desired gene is isolated in its native form; (2) the gene is characterized
and modified into a shorter DNA form at the molecular level; (3) the desired DNA sequence is inserted into an appropriate vector which can be integrated into the chromosomal DNA of the target organism; and (4) the
vector containing the foreign DNA is introduced into the organism. 6 The
foreign gene, which can either add to or replace the native gene, remains
part of the transformed organism permanently.7
The rapid development of modern molecular biology techniques has
made recombinant genetic engineering a feasible and routine practice in
numerous laboratories around the world. Compared to the traditional genetic approaches, recombinant genetic engineering has two major advan2 See STEPHEN A. BENT ET AL., INTELLECTUAL PROPERTY RIGHTS IN BIOTECHNOLOGY

WORLDWIDE 19-28 (1987).
3 See id. at 20 (for instance, chemical agents and irradiation have been used to induce
mutagenesis of DNA).
4 Id. (induced mutagenesis allows breeders quicker and more direct access to genetic materials than the traditional process, where breeders only can artificially select mutants based
on organismic
criteria).
5
1d.
6 E.S. VAN DE GRAFF, PATENT LAW AND MODERN BIOTECHNOLOGY
20 (1997).
7

1d. at 29.
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tages. First, it is time and cost efficient. Most of the equipment and facilities required for genetic transformation are commercially available and relatively inexpensive. Also, modem DNA vectors are highly efficient at
delivering the foreign DNA into the chromosomal DNA of the target organism.8 Second and more importantly, equipped with the knowledge about the
functions and characteristics of foreign DNA, a genetic engineer may predict the traits of the transformed organism and thus "overcome the randomness of heritability associated with conventional plant and animal
breeding." 9
Recombinant genetic engineering has profoundly changed agriculture
as well as the biomedical and pharmaceutical industries. In plant agriculture, researchers have successfully added disease resistance genes, herbicide
tolerance genes, and pest resistance genes into various crops.'° Crops can
also be engineered to be more nutritious and productive."' Furthermore,
through genetic engineering, livestock animals have become more productive and have acquired more disease resistance.' 2 For example, transgenic
swine consume significantly less feed but arrive at market weight faster
than their native counterparts.' 3 The pharmaceutical industry has also increasingly utilized genetically modified animals or microorganisms to produce drugs to5 cure or alleviate diseases, 14 such as AIDS, cancer and
hepatitis B.1
China's biotechnological market has grown faster than any other in the
world in the past decade.' 6 To narrow the gap between its biomedical industry and those of developed countries, China has employed two main approaches. First, China decided to focus its research and resources in several
key fields, one of which is genetic engineering. 17 For example, China's
State Science and Technology Commission ("SSTC") launched several
programs to support biotechnology research, development, and commercialization.' 8 Second, China has vigorously campaigned for investments
from foreign pharmaceutical companies and has enjoyed tremendous suc8

1d. at 22.
9 Reid G. Adler, Controlling the Applications ofBiotechnology: A CriticalAnalysis of the
Proposed Moratorium on Animal Patenting,I HARV. J.L. & TECH. 1, 18 (1988).

Id
"Id
'Id.at 18-21.
3
1d. at 21.

14Akim F. Czmus, Biotechnology Protectionin Japan,the European Community, andthe
UnitedStates, 8 TEMP. INT'L. & COMP. L.J. 435 (1994).
5
d.at 436.
16 Market Research Studies. Expert Market Devises Improving 1997 Global Market,
BIOMEDICAL MARKET NEWSL., Apr. 30, 1997.
11Development of Biomedicine in China, MARKETLETTER, Sept. 8, 1997.

18Andrew Beckman, Biomed & Biotech New Business Opportunities in China (PRC),
BIOMEDICAL MARKET NEWSL., Apr. 1, 1996.
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cess. For example, by 1997 China had received a $4.1 billion capital investment from about 1,500 foreign pharmaceutical companies,' 9 including
Merck from the United States, Genset from France, and Kirin Brewery Co.
from Japan. 20 As a result, China is viewed in the international biotechnology arena as an emerging power.
III. THE BENEFITS AND RISKS OF GMOS
GMOs, like any other innovation, provide both benefits and risks.
Many of the major benefits of GMOs have already been mentioned. For
example, genetic engineering can significantly increase the productivity of
crops and livestock, which may be extremely vital to deal with the expected
food shortfalls accompanying the rapid expansion of the world's population. Genetic engineering can also be used to improve the quality of food.2'
Furthermore, the drugs produced by GMOs have been tremendously beneficial to human health because of their high quality, ability to be produced
in large quantities and relatively low prices. In addition, adding certain
disease genes to animals can provide researchers with non-human models to
research the cures for diseases such as hypertension and AIDS. 2
The risks associated with GMOs can be divided into three categories:
environmental, economic and those affecting human health.23 The environmental arguments against patenting GMOs focus on GMOs' effects on
the ecosystem and the reduction of biodiversity.2 4 Some commentators argue that the introduction of GMOs "into an ecosystem might affect the dynamics of the ecosystem or the gene pool of wild relatives., 25 For example,
crops with herbicide resistance genes may transfer these genes to weeds,
thus creating a major threat to the environment.2 6 Furthermore, patenting
opponents point out that humans often lack the wisdom and foresight as to

19Dan Gallagher, China Offering Biotech Firms Big Opportunities, SAN DIEGO DAILY
TRANSCRIPT, June 17, 1997, at Al.

20 Leslie Cataldo, A Dynasty Weaned from Biotechnology: the Emerging Face of China,

26 SYRACUSE J. INT'L L. & CoM. 151, 164-66 (1998).
21 Carrie F. Walter, Intellectual Property Law Review 1999, 31 INTELL. PROP. L. REV.
195,219 (1999).

22 Patents and the Constitution: Transgenic Animals: HearingsBefore the Subcomm. On

Courts, Civil Liberties and the Administration of Justice of the House of Representative

Comm. On the Judiciary, 100th Cong. 36-37, 47-49 (1988) (testimony of Thomas E. Wagner, Professor of Molecular Biology and Director, Edison Animal Biotechnology Center,
Ohio State University).
23 Henrique Freire de Oliveira Souza, Genetically Modified Plants: A Need for International Regulation, 6 ANN. SURV. INT'L & COMP. L. 129, 138 (2000).
24 Adler, supra note 9, at 38-43.
25 Souza, supra note 23, at 139.
26 Michael A. Whittaker, Reevaluating the Food and Drug Administration'sStand on Labelling Genetically EngineeredFoods, 35 SAN DIEGO L. REV. 1215, 1220-21 (1998).
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the disastrous consequences of interfering with the environment. 27 For instance, humans released the gypsy moth and kudzu vine into the environment and caused extremely serious damages.28
The view that GMOs represent an environmental threat is not necessarily the predominant view, however. For example, a report prepared for the
National Academy of Sciences concluded that there was "adequate knowledge of the relevant scientific principles, as well as sufficient experience
with recombinant DNA engineered organisms, to guide the safe and prudent
use of such organisms outside research laboratories.,, 29 Furthermore, it is
relatively easy for scientists to monitor and control
the transfer of genes be30
tween GMOs and wild organisms by mating.
Opponents of animal and plant patenting also argue that the introduction of GMOs might result in loss of biodiversity if such new varieties
dominate. 31 The loss of biodiversity could have disastrous consequences in
agriculture because high genetic uniformity means that the agricultural
crops and livestock are more susceptible to common diseases or pest infestation.3 2 For example, more than ninety-five percent of chicken eggs are
from a single breed, White Leghorns, and more than ninety percent of milk
is from the breed Holstein.33 Thus, a lethal disease to either breed could
ruin the milk or chicken egg industry.3 4
Patenting advocates respond that there is no causal link between patents and a decrease in biodiversity. 35 As one commentator points out, there
already has been a decrease in biodiversity in the livestock industry because
of increased corporate consolidation; genetic engineering might reverse this
trend by adding foreign genes into crops and creating new varieties.36
The main economic argument against the patenting of GMOs is that
the initial acquisition prices and subsequent royalties of GMOs will increase costs for both farmers and consumers. 37 However, this view fails to
consider the basic principles of economics, as farmers would not acquire or
27 Rebecca Dresser, Ethical and Legal Issues in Patenting New Animal Life, 28
JURIMETRICS J.

399, 411-12 (1988).

28id
29 Report from Committee on the Introduction of Genetically Engineered Organisms into

the Environment to the Council of the National Academy of Sciences, Introduction of Recombinant DNA-Engineered Organisms into the Environment: Key Issues 6 (1987) (on file
with author).
30 Dresser, supra note 27, at 414.
" See Adler, supra note 9, at 43.
'2Id.at 44.
33Barry Hoffmaster, The Ethics of Patenting Higher Life Forms, 4 1. P. J. 1, 14 (1988).

(Intellectual
Property Journal?)
34

id.
35Adler, supra note 9, at 44-46.
36 Id. at 45-46.
37Walter, supra note 21, at 211.
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use GMOs if their economic benefits did not outweigh the costs.
The question of whether GMOs may be safely used as food for humans
remains unanswered. As of today, there is no answer because of a lack of
scientific data and a lack of uniformity in the safety standards of different
countries. 38 However, the bottom line is that there are already many lawful
but unsafe foods on the market.3 9
IV. ETHICAL ISSUES OF ANIMAL PATENTING

Opposition to animal patenting is mainly based on ethical grounds. In
general, patenting critics express concern about several issues: human arrogance, devaluation of human life, and animal welfare.4 °
Patenting opponents argue that patenting reflects a view of life which
is completely human-centered. 4' Animal patents allow the commercialization of animals' lives and reflect the view that all natural resources are for42
human exploitation and animals are no different from chemical products.
However, this argument is not persuasive because for thousands of years
humans have treated animals as properties by buying, selling, and using
them for humanity's commercial and consumer needs.43

Patenting opponents also argue that by creating and patenting genetically engineered animals, humans violate animals' right to exist as separate
species. 44 In response, patenting advocates point out that there are no absolute rules to separate species, and humans have already created many genetically altered animals through traditional breeding techniques.4 5
A stronger argument against animal patenting is that patenting animals
would eventually lead to the patenting of human life and the creation of
human-animal hybrids.46 One commentator analogizes the problem to a
slippery slope by pointing out that humans will inevitably become patentable subject matter if animals are patentable because it is theoretically
and empirically impossible to draw a clear distinction between animal and
human life. 47 Furthermore, adding human genes to animals may create human-animal hybrids.48 As they have successfully created a "geep," a hybrid
of goat and sheep, scientists may as well create a hybrid of human and

38 Souza, supra note 23, at 139-40.
39 Id. at 140.

See Dresser, supranote 27, at 410; Adler, supra note 9, at 46-50.
41 See Dresser, supranote 27, at 411.
40

Id.
41 Id. at 413.
44 See Adler, supra note 9, at 48-49.
45 See Dresser, supranote 27, at 413-14.
42

46

See Hoffmaster, supra note 33, at 11; Dresser, supra note 27, at 415.

47 See Hoffmaster, supra note 33, at 11-12; Dresser, supra note 27, at 416.

48 Dresser, supra note 27, at 415-16.
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chimpanzee. 49 Patenting opponents argue that this disturbing scenario will
not only reduce the value of human life to chemical molecules, but also
"violate the cultural taboo against procreation between animals and hu50
mans."
In responding to this line of criticism, the proponents of animal patenting argue that currently the quantity of human genes added to animals is too
small to create human-animal hybrids. 5' More importantly, they argue that
the genuine ethical concern about human-animal hybrids should be addressed in the policies regulating genetic engineering research, not in patent
law.52

Finally, patenting opponents argue that allowing animal patenting
would stimulate transgenic research and result in more animal suffering.53
However, this line of argument overlooks the beneficial side of genetic manipulation. 54 Transgenic research can produce animals with stronger resistance to diseases. 55 Patenting will also benefit animals because genetic
engineering usually results in less unplanned negative results occurring in
traditional breeding.56
In summary, many of the ethical arguments against animal patenting
are not compelling. Furthermore, many of these concerns should be addressed in policies regulating transgenic research, not patent law.
V. INTERNATIONAL INTELLECTUAL PROPERTY PROTECTION FOR

GMOs

The patentability of GMOs, especially genetically modified animals, is
a highly controversial issue. Most countries either allow plant varieties to
be patented, provide an effective sui generis system, or some combination
of the two. They probably find that the need to provide more food to the
geometrically expanding population outweighs potential environmental
risks. However, many countries refuse to provide any protection, patent or
otherwise, to new animal varieties, despite the fact that the creation of new
animal varieties involves very similar techniques to those used to produce
new plant varieties.5 7 The discrepancy of treatment between these countries
is mainly due to varying conceptions about humanity's ethical duties toward animals.

49 id,

'old at 416.
5'Id. at 416-17.
5
Id. at 417.
51See id. at 422-23.
54See Adler, supra note 9, at 37.
15See id.
56See Dresser, supra note 27, at 423.
57BENT ET AL.,

supra note 2, at 24-25.
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A. GMOs Patentable in the U.S.
In the landmark decision Diamond v. Chakrabarty,58 the U.S. Supreme
Court held that a living microorganism is patentable subject matter under §
101 of the Patent Act. 59 The Court further held that living matter is patentable if it is the result of human intervention. 60 In 1987, the Commissioner of the Patent and Trademark Office ("PTO") announced that animals
may be patented. 6 The first animal patent was issued in 1988 to a transgenic non-human mammal, which was genetically engineered to be more
susceptible to carcinogens.62
Plant varieties are also protected by a variety of Acts. Asexually reproduced plant varieties are patentable under the Plant Patent Act
("PPA"). 6 3 The Patent Variety Protection Act ("PVPA") of 1970 provides
patent-like protection to sexually reproduced plants. 64 Additionally, according to Chakrabarty,plants may also be patented.
B. Union for the Protection of New Varieties of Plant ("UPOV")
In many civil law countries, plant varieties are not patentable because
they lack novelty, invention, utility, or the ability to replicate or reproduce.65 Instead, these countries established "separate legal regimes for
spe66
UPOV.
into
developed
later
which
varieties"
plant
of
protection
cial
UPOV protects biological innovations which do not meet the requirements
of patent protection.6 7 Thus, both plant and animal varieties fall within the
protection zone of UPOV. It should be noted, however, that UPOV protects
68
only the whole plant or animal, not its genes or constituent chemicals.

447 U.S. 303 (1980).

5935 U.S.C. § 101 (1952).
60Diamond, supra note 58, at 309.
61 1077 OFFICIAL GAZ. PAT. OFF. 24 (1987).
62U.S. Patent No. 4,736,866 (issued Apr. 12, 1988).
6335 U.S.C. §§ 161-164 (1954).

647 U.S.C. § 2321-2583 (1982).

65See Geertrui Van Overwalle, Patent Protectionfor Plants: A Comparisonof American
and European Approaches, 39 J.L. & TECH. 143, 148 (1999).
66Lester Ross & Libin Zhang, Agricultural Development and Intellectual PropertyProtection for Plant Varieties: China Joins the UPOV, 17 UCLA PAC. BASfN L.J. 226, 229
(1999).
67See Klaus Bosselmann, Plants and Politics: The InternationalLegal Regime Concerning6Biotechnology and Biodiversity, 7 COLO. J. INT'L ENVTL. L. & POL'Y 111, 122-23 (1996).
1ld. at 124.
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C. Trade Related Aspects of Intellectual Property Rights ("TRIPS")
TRIPS, a division of the World Trade Organization ("WTO"), requires
member states to provide intellectual property protection for all biotechnological inventions. 69 Concerning plant varieties, TRIPS requires WTO
members to "provide for the protection of plant varieties either by Patents
or by an effective sui generis system or any combination thereof., 70 Developed countries embrace TRIPS because this universally-accepted system
provides much needed protection for their advanced biotechnology industries. 7' In 1990, TRIPS proposed to allow patenting living organisms,
which include microorganisms, plants and animals. 72 However, this proposal was opposed by developing countries and did not pass. 73 Since its entry into the WTO in November 2001, China has been bound by TRIPS to
provide required intellectual property protection for biotechnological inventions.74
VI. INTELLECTUAL PROPERTY PROTECTION FOR GMOs IN CHINA

China has experienced tremendous economic growth since it opened
its doors to western countries in 1978. China has also rapidly transformed
its intellectual property laws according to western models. In 1984, China
passed its first patent law that was compatible with international standards. 75 That law extended fifteen years of patent protection to inventions
and five years to utility models and designs after the patent applications
were filed.76 Pharmaceuticals were not patentable subject matter under the
1984 law.77 The 1993 amendments to the patent law extended protection to
chemicals and pharmaceuticals.78 In addition, patent terms were extended

69

General Agreement on Tariffs and Trade, Oct. 30, 1947, 61 Stat. A-11, T.I.A.S. 1700,

55 U.N.T.S. 194.
70 Agreement on Trade Related Aspects of Intellectual Property Rights [hereinafter
TRIPS agreement], Art. 27.3(b).
71See David G. Scalise & Daniel Nugent, Comment, InternationalIntellectual Property
Protectionfor Living Matter: Biotechnology, Multinational Conventions and the Exception
for Agriculture, 27 CASE W. RES. J. iNT'L L. 83, 114-115 (1995).
72Id
73Cataldo, supra note 20, at 158.

74See Thomas T. Moga, China Changes Patent Law to Comply with TRIPS, NAT'L L.J.,
July 23, 2001, at C15.
75See Jill Chiang Fung, Note, Can Mickey Mouse Prevail in the Court of the Monkey

King? Enforcing Foreign IntellectualProperty Rights in the People's Republic of China, 18
Loy. L.A. INT'L & COMP. L. REV. 613, 627 (1996).
76See David B. Dreyfus, Note, Confucianism and Compact Discs: Alternative Dispute
Resolution and its Role in the Protection of United States Intellectual Property Rights in

China, 13 OHIO ST. J. ON Disp. RESOL. 947, 952 (1998).
77Id.

78See Fung, supra note 75, at 632.
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under the 1992 amendment. 79 Inventions are entitled to a twenty-year protection while utility models and designs are protected for ten years. Thus,
the amended Patent Law of 1993 was in greater conformity with international standards.
Despite this greater conformity, however, plant and animal varieties
are not patentable, although China permits the patenting of microbiological
processes and their derivative products. 80 The reasons to deny patent protection for plant and animal varieties are not clear.8'
VII. PLANT VARIETY RIGHTS
With an enormous and ever expanding population, China has realized
that the focus of agricultural science and technology is on developing,
through genetic engineering, new animal and plant varieties with higher
quality and productivity. 82 However, the lack of a patent or sui generis protection system deprives breeders of the incentive to expend resources on research and development of new plant or animal varieties. As a result, the
technical level of China's agricultural and life sciences lags behind that of
developed countries and the gap is still widening.83
In 1997, China passed the Regulations on the Protection of New Varieties of Plants (the "Plant Variety Regulations") with the objective of promoting the development of agriculture and forestry.84 To qualify for Variety
Rights, the plant varieties must be (1) novel, (2) distinctive from all other
varieties prior to application, (3) stable with regard to their relevant properties after reproduction, (4) properly named, and (5) belonging to a plant
85
species included in the State plant varieties catalogue.
Once awarded Variety Rights, the breeder enjoys an exclusive right to
the plant variety. Specifically, "no unit or individual may for commercial
purposes (i) produce or sell any breeding material for which Variety Rights
have been awarded or (ii) make repeated use of such breeding material to
create new varieties. 86 A Variety Rights holder can subject infringers to

79See Patent Law of the People's Republic of China, art. 45 (1993) (P.R.C.) [hereinafter
China Patent Law].
80See Davis Hill & Judith Evans, Chinese Patent Law: Recent Changes Align China
More Closely With Modern InternationalPractice, 27 GEO. WASH. J. INT'L L. & ECON. 359,

364 (1993-1994).
8 See China Patent Law, art. 25 (1993) (P.R.C.).
82 Ross & Zhang, supranote 66, at 230-31.

83 See Bosselmann, supra note 67, at 121-22.
84 See the Regulations of People's Republic of China on the Protection of New Varieties
of Plants [hereinafter Plant Variety Regulations], art. 1 (1997), available at http://
www.cnpvp.net/old-www/rules-and regulations.htm.
85 See Plant Variety Regulations, art. 13-17.
86 Ross & Zhang, supra note 66, at 232-33.
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87
both civil litigation and administrative mediation.
Variety Rights provide narrower protection for plant varieties than patents.88 For instance, anyone can use a plant variety under the protection of
Variety Rights for breeding or other scientific research activities without
compensating the Variety Rights holder.8 9 Farmers can also freely utilize
the "breeding material for their own use." 90 Furthermore, once awarded the
Rights, most plant varieties are protected for only 15 years compared to the
20-year term under the Patent Law. 9' In China, both the Patent Law and the
Plant Variety Regulations have a compulsory licensing provision.92 Under
this provision, the approving authority can compel an awardee to license his
patent or new plant variety even at below-market prices or to his competitors. 93 This provision is rather problematic because it fails to clearly state
restrictions on the exercise of compulsory licensing.94
Despite any shortcomings, the Plant Variety Regulations comply with
the TRIPS agreement, which requires WTO member nations to provide at
least one effective protection system for plant varieties.95 Although it is not
very clear as to why China chose the Plant Variety protection over patent
protection, most developing countries oppose the idea of patenting living
organisms because they cannot afford the expensive licensing fees of
GMOs and also because much of the starting genetic material used for
GMOs is native to their lands.96

VIII. RESOLUTION OF PATENT DISPUTES

China developed a two-track system to enforce intellectual property
rights. The first track is the administrative resolution where the infringed
party files a complaint with local administrative offices that are responsible
for patent-related affairs. 97 Once a complaint is filed, the administrative authorities first mediate the disputing parties to a reconciliation or settlement.
If mediation fails, the patent administrative authorities have the power to
order either monetary compensation or an injunction against the infringer.98
Administrative resolution remains the dominant method for patent87
88

See Plant Variety Regulations, supra note 84, at art. 39.
Ross & Zhang, supra note 66, at 233.

g9Id.

90 Id.

91See Plant Variety Regulations, supranote 84 at art. 34.
at art. 11. See also China Patent Law, supra note 79, at art. 57-58 (1993).
92 See id.
93Ross & Zhang, supra note 66, at 233.
9'Id. at 233-34.
95
at 230.
Id.
96 See Cataldo, supra note 20, at 155.
97See Moga, supra note 74, at C16. These offices are also called Patent Administrative
Authorities. See Hill & Evans, supranote 80, at 372.
98 See Hill & Evans, supra note 80, at 373.
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related disputes in China for various reasons. The Chinese have a tradition
of preferring conciliation between adversarial parties over litigation because
of their long-held concept of "amity above all." 99 The administrative approach is also fast and efficient-a dispute can be resolved within days after
the complaint is filed.' 00 Part of the reason for the efficiency is that the local authorities are closely connected to other local agencies, whose cooperation is instrumental to the enforcement. 10 1 Furthermore, the administrative
approach is an inexpensive alternative to litigation because of its relatively
02
low costs. 1
The administrative approach cannot replace the judicial approach,
however. Importantly, it lacks the deterrent feature of the judicial approach
because the Patent Administrative Authorities cannot impose criminal penalties on the infringers. In addition, the administrative approach often results in limited temporary relief because the victim of a government raid
is
03
distributor.'
the
but
products,
infringing
the
of
source
the
not
usually
On the other hand, the second track, the judicial approach, offers lasting and deterrent remedies, including compensatory damages, punitive
damages, or criminal punishment. 10 4 However, the judicial approach is not
the preferred method of patent disputes. The process is slow and many
judges are not adequately trained with regard to patent-related issues.10 5 In
addition, the financial burden on the aggrieved party can be substantial because the complaint filing fees are proportional to the requested amounts of

damages. 106
IX. THE EFFECTS OF THE 2001 AMENDMENTS TO CHINA'S PATENT LAW
The 2001 amendments brought China's Patent Law more in line with
the TRIPS agreement.'0 7 Specifically, there are four major changes worth
noting. First, the pre-2001 Patent Law allowed compulsory licensing of
patents under a broad provision,'0 8 which was inconsistent with Article 31
of the TRIPS agreement. 0 9 The 2001 amendments define the subject mat99

d. at 392.

00 See Moga, supra note 74, at C16.
101 See

Hill & Evans, supra note 80, at 392.
Id. at 376.
103 See Moga, supra note 74, at C17.
02

0o4
id.

105 Id.
106 id.
07

' d. at C15.

lo See China Patent Law, supra note 79, at art. 53 (1993) (permitting compulsory licens-

ing to a patent when the exploitation of a later and more advanced patent depends on the exploitation the earlier patent).
109 TRIPS agreement, supra note 70, at art. 31 (permitting compulsory licensing only under reasonably well-defined circumstances).
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ter and relative value of a patent that could be subject to compulsory licensing.l° Furthermore, the time, scope, and duration of compulsory licenses
111
have also been amended to be consistent with the TRIPS agreement.
Second, the 2001 Patent Law provides a patentee with the exclusive
right of sale. 1 12 Although the TRIPS agreement requires WTO member nations to award patent holders the right to "exclude others from offering for
sale the patented products or products directly obtained by patented processes," China's former Patent Law did not have such a provision.1 13 The
2001 amendment
to Article 11 of the Patent Law erased the inconsis114
tency.
Third, the amended Patent Law shifts the burden of proof to the alleged
patent infringer in infringement cases. Article 57 of the new Patent Law
states that "[f]or any dispute as to infringement regarding the patent for invention which relates to a process for the manufacture of a new product, the
entity or individual that produces the same products has responsibility to
provide evidence demonstrating that its process is different from the patented process. ' 15 This change makes China's Patent Law compliant with
the TRIPS agreement.' 6
The last major change to the Patent Law is the allowance of injunctive
relief as a critical mechanism of patent enforcement.1 17 This18amendment is
also consistent with Article 44(1) of the TRIPS agreement.'
The 2001 amendments notwithstanding, challenges for the inventors
still remain. Under the new Patent Law, animals and plants are still not
patentable subjects. 1 9 Although plant varieties enjoy protection under the
Plant Variety Regulations, animal varieties are not protected by any law.
Furthermore, the provisions regarding compulsory licensing in both the
Patent Law and the Plant Variety Regulations are too broad and thus not in
compliance with the TRIPS agreement. For example, the Patent Law does
not clearly define the restrictions on the exercise of compulsory licensing
power. 120 The Patent Law also fails to state that a patent holder shall be
paid "adequate remuneration in the circumstances" as required by Article
31 (h) of the TRIPS agreement.12 1
10 Moga,

supra note 74, at C15.

1See id. at C16. See also China Patent Law, supra note 79, at art. 52 (2001).

112See Moga, supra note 74, at C15.
13 Id. See also TRIPS agreement, supra note 70, at art. 28.

114
See also China Patent Law, supra note 79, at art. 11 (2001).
"5 See China Patent Law, supra note 79, at art. 57 (2001).
116 See TRIPS agreement, supra note 70, at art. 34(1).

117
See China Patent Law, art. supra note 79, at 61 (2001).
118
See TRIPS agreement, supra note 70, at art. 44(1).
i"9
See China Patent Law, supra note 79, at art. 25 (2001).
120

See Moga, supra note 74, at C16.

121

TRIPS agreement, supra note 70,at art. 3 1(h).
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Because the 2001 Patent Law remains silent about the patentability of
animal varieties, the next section will mainly discuss whether new animal
varieties should enjoy intellectual property protection in China.
X. SHOULD NEW ANIMAL VARIETIES BE PROTECTED IN CHINA?

China's ever growing population and increasing demand for food
might require the country to provide intellectual property protection for new
animal varieties. Such protection of animal varieties may encourage both
domestic and foreign investment in biotechnology research and development in China. Furthermore, protection would promote the transfer of biotechnologies to China. However, due to economic concerns, animal patents
might be unwise. A sui generis protection system such as the Plant Varieties Regulations might be more appropriate.
XI. INTELLECTUAL PROPERTY PROTECTION FOR ANIMAL VARIETIES
IMPORTANT TO CHINA

Patent protection grants an inventor exclusive rights to make, use, and
sell the patented invention.' 22 The promise of protection induces inventors
to spend resources on research and development, thus advancing technology by stimulating innovation. 23 This is especially true for the biotechnology industry because the costs of developing new drugs or GMOs can be
intimidating. 124 The absence of intellectual property protection for new
animal varieties, including genetically modified animals, can harm animal
research. For example, the biomedicine and biotechnology industries
would have no incentive to develop and commercialize the genetically
modified animals used to produce important drugs to cure human diseases. 125 Farmers may also suffer economic losses where intellectual property protection does not exist because there would be fewer transgenic
livestock animals with higher productivity or improved resistance to diseases. 126 Intellectual property protection for new animal varieties is particularly important to China because of its growing need for food.
XII. CHINA'S POPULATION EXPANSION NECESSITATES MORE FOOD
ANIMALS

Animals provide the major source of protein for human beings. 127 The
122See Adler, supra note 9,at 12.
123
Id.
124 See VAN DE GRAAF, supra note 6,at 38.
125See Adler,supra note 9,at 7-8.

126Id.at 8.
127
Id.at 33 (although the data about the composition of the Chinese diet are not available, in the United States, "food animals provide seventy percent of the protein, thirty-five
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world's population is expanding geometrically; therefore, the demand for
food animals is also increasing rapidly.' 28 The problem of inadequate food
supplies becomes more pressing as the use of land has reached saturation
level.
With 1.25 billion people, China is the most populated country in the
world. 129 Although China is currently able to feed its population, the traditional agricultural crops and livestock will probably not be able to meet the
increasing demand of food coupled with its expanding population. The
most viable solution to this problem is the development and adoption of
more productive and nutritious crops and livestock. 30 Modem genetic engineering technologies can create transgenic livestock that grow faster, consume less food, and are leaner and more nutritious than traditional breeds.' 3 '
cattle produce more milk per animal while conFurthermore, transgenic
32
suming less food.'
Without intellectual property protection of genetically modified animals, however, the biotechnology industry in China would have little incentive to invest in the research and development of more productive livestock.
Furthermore, without protection, foreign biotechnology companies have little incentive to introduce their new animal varieties into China. Therefore,
transgenic animals should be protected in China to stimulate agricultural
innovation and promote cross-border technology transfers, which will in
turn help solve the anticipated food shortfall.
XIII. INTELLECTUAL PROPERTY PROTECTION FOR GENETICALLY
MODIFIED ANIMALS WILL ACCELERATE THE DEVELOPMENT OF CHINA'S
BIOMEDICINE AND PHARMACEUTICAL INDUSTRIES
The advent of DNA recombinant technologies and genetically modified animals promises major breakthroughs for the biomedicine and pharmaceutical industries. Many human genes have been transferred into
laboratory animals to study their regulations and functions. For example,
the cellular receptor for the AIDS virus only exists in humans and chimpanzees.133 While experiments on chimpanzees are extremely expensive, introducing the receptor gene into mice can produce an inexpensive animal

percent of the energy, eighty percent of the calcium, sixty percent of the phosphorus, and
significant
proportion of vitamins and minerals consumed").
128 id.
129

See Taylor, supra note 1.

130 OFFICE OF TECHNOLOGY

ASSESSMENT,

U.S. CONGRESS, PUB. No. OTA-F-285,

TECHNOLOGY, PUBLIC POLICY, AND YHE CHANGING STRUCTURE OF AMERICAN AGRICULTURE

3 (1986).
131 See Adler, supra note 9, at 5.
132id.
113Id. at

21-22.
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model to study AIDS and to screen AIDS drugs.1 34 Research on transgenic
animals bearing human genes can greatly enhance Our ability to understand
human and animal physiology, including the immune system, genetic defi35
ciencies, embryonic development, and viral diseases. 1
Transgenic animals may also function as molecular farms to produce
drugs to cure or alleviate human diseases. For example, transgenic sheep
were created to produce human blood clotting factors used for the treatment
of hemophiliacs.' 36 Transgenic mice were also created to produce tissue
plasminogen activator ("TPA") used to treat heart attacks.137 Compared to
the chemical synthesis approach, the "molecular farming" approach is much
more accurate and cost-efficient.
Intellectual property protection is the decisive reason why pharmaceutical companies invest in research and development.138 Because of the high
commercial stakes involved, pharmaceutical companies need to protect
their products against imitations after they introduce the products into the
market. Given the fact that the costs of GMO development are extremely
high and many biotechnological innovations are made by small start-up
companies, intellectual property protection is necessary to allow small
companies to recover their expenses. 139
China has invested heavily on genetic and protein engineering during
the last decade in order to raise its biotechnology industry level to that of
the developed countries.140 For example, China's State Science and Technology Commission established the "Torch Program" to promote the commercialization, industrialization, and globalization of China's new
technologies.
The biotechnology part of this program focuses on the research and development of biopharmaceutical products, such as hepatitis B
vaccines and anti-tumor drugs. 42 The Chinese Academy of Sciences has
also sponsored many biomedical projects, including the development of in43
terleukin-2, interferon alpha, and hepatitis B vaccines.
Although the majority of China's biomedical research is funded by the
government, China plans to significantly decrease governmental funding
and eventually make private firms, both foreign and domestic, finance the

134 Id.
35 Camper, Research Application of TransgenicMice, 5 BIOTECHNIQUEs 638
(1987).
36 Adler, supra note 9, at 5.

137

id

138 See VAN DE graff, supra note 6, at 37.
"' Id. at 38.
140 See Development of Biomedicine in China, supranote 17.

141See Beckman, supra note 18.
142 Id.
143See Development of Biomedicine in China, supra note
17.
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research and development of biomedical products.144 However, without
proper intellectual property protection for new animal varieties, private
firms have little incentive to risk the intimidating costs of research and development. As a result, not only will China's agriculture suffer the absence
of more productive, nutritious, and disease resistant livestock, but also the
Chinese people will be deprived of the access to the high-quality and inexpensive drugs produced by transgenic animals. The lack of intellectual
property protection for new animal varieties will directly defeat China's
goal of developing a competitive biotechnology industry.
XIV. TRADE SECRET LAW NOT A SUFFICIENT PROTECTION FOR
GENETICALLY MODIFIED ANIMALS

In the absence of appropriate intellectual property protection for genetically modified animals, inventors will have to resort to trade secret law
to safeguard their investment on research and development. Even if trade
secret law can provide sufficient protection for genetically modified animals, it will deprive society of cutting-edge biotechnological information45
and cause people to waste resources in penetrating commercial secrecy.
The more troubling problem, however, is that trade secret law is not a
sufficient protection for genetically modified animals because of the nature
of genetic engineering techniques. Trade secret law requires some degree
of secrecy and also requires the inventors undertake spend reasonable efforts to protect the secrecy. However, some of the unique attributes of genetically modified animals make them very difficult to protect. 46 For
example, a misappropriator can easily recreate a transgenic animal by stealing the DNA sequence written in a piece of paper.' 47 Advances in genetic
engineering techniques make gene transformation a routine practice in an
adequately equipped laboratory. Therefore, once a competitor misappropriates a genetic code, he can easily recreate the transgenic animal.
In addition, once a misappropriator obtains a genetically engineered
animal, he can regenerate many offspring without even understanding the
genetic information embodied in the animal. The self-generating nature of
organisms is the exact attribute that makes transgenic animals highly desirable, but 1it48also inevitably makes the protection of animal variety property
difficult.
Trade secret laws in the United States and some other countries also
require a trade secret to have "an established commercial value at the time

144See Beckman, supra note 18.
145R. POSNER, ECONOMIC ANALYSIS OF LAW
146See BENT ET AL., supra note 2, at 346.

147id.

141
id.at 346-47.

2d 53 (1977).
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of theft."'149 This requirement poses another problem for the protection of
genetically modified animals, because many biotechnological inventions do
not have established commercial values if they are still in the basic research
stage. 15 Although they contain substantial research information and are on
the verge of being developed into commercial products,' 51 some countries
have denied such genetically modified animals trade secret protection. 152
Thus, trade secret law cannot provide sufficient protection for genetically modified animals because of their unique attributes. A more exclusive
protection system is needed to safeguard the high costs biotechnology companies spend on the research and development of transgenic animals.
XV. INTELLECTUAL PROPERTY PROTECTION FOR GENETICALLY
ENGINEERED ANIMALS PROVIDED IN MANY COUNTRIES

Many developed countries have provided patent protection for living
organisms, including genetically modified animals. In 1969, Hungary enacted a law to extend patent protection to animals if they met the requirements of "distinguishable, novel, homogenous and stable."' 53 Germany in
1969 decided that animals were patentable if their production is repeatable. 54 Higher life forms, including animals, are also patentable in Austra55
lia.'
In the landmark Chakrabartydecision, 56 the U.S. Supreme Court concluded that Section 101 of the Patent Act should be broadly construed and
patentable subject matter includes "anything under the sun that is made by
man." 57 Following the Chakrabartydecision, PTO issued the first animal
patent to a genetically engineered mammal in 1988.158 In 1982, Canada
also followed the Chakrabartydecision and treated living organisms as patentable subject matter.' 59 Due to the high economic stakes involved with
genetically modified animals in biomedicine and biotechnology industries,
many more countries are expected to join the trend to include animals in
patentable subject matter.

149Id. at

150
id.
151id.
152 Id. at

348.
355.

53Hungarian Patent Law, art. 71 (1969).
54See Adler, supra note 9, at 30.
55

'

56

Id. at 31.

47 U.S. 303 (1980).

Id. at 309, (citing S. REP. No. 1979, 82d Cong., 2d Sess. 5 (1952); H.R. REP. No. 1923,
82d Cong., 2d Sess. 6 (1952)).
158
U.S. Patent No. 4,736,866 (issued Apr. 12, 1988) (patent issued to a transgenic nonhuman mammal which was genetically engineered to be more susceptible to carcinogens).
'59
See Adler, supra note 9, at 30-31.
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XVI. CHINA SHOULD PROVIDE Sui GENERiS SYSTEM PROTECTION FOR
GENETICALLY MODIFIED ANIMALS

Although intellectual property protection for genetically modified animals is important to China's agriculture and biotechnology industries,
China should not adopt patent protection because of economic reasons.
Due to historical reasons, the technical level of China's life sciences research lags behind that of developed countries and China's intellectual protection system is geared more towards the importation of advanced
technologies. As a developing country, China prefers to receive free transfer of cutting-edge biotechnologies. 160 Without the benefit of receiving free
technology transfer, China cannot afford the rights to use costly biotechnology products.1 61 This is particularly true for the biotechnological inventions
concerning agricultural livestock. Genetically engineered livestock can be
more productive, nutritious, and disease resistant. However, Chinese farmers may be deprived of the benefits of these improved livestock because of
the costly acquisition and royalty fees.
A sui generis protection system such as the Plant Variety Regulations
may serve China better. An animal variety protection system, similar to the
Plant Variety Regulations, would award an animal breeder exclusive rights
to his new animal variety. Under such a system, other units or individuals
cannot for commercial purposes produce or sell the protected variety, or use
it to create new varieties. In this way, a sui generis protection system may
adequately protect the intellectual property rights of biotechnology firms
and safeguard their investment on the research and development of transgenic animals.
A sui generis protection system, however, should impose some limitations on the animal variety rights. Like the Plant Variety Regulations, it
should allow farmers to utilize genetically engineered livestock for their
own use without compensating the animal variety rights holder. Furthermore, it should allow others to freely use the protected variety for breeding
or other scientific research activities. In this way, a sui generis protection
system would alleviate China's financial burden to pay for the rights of new
biotechnological inventions.
XVII. CONCLUSION

China should extend intellectual property protection for genetically
modified animals for a variety of reasons. The increasing demand for food
animals can only be met by the development and adoption of genetically
improved agricultural livestock that are more productive, nutritious, and

160Cataldo,
161id.

supra note 20, at 155.
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disease resistant. Intellectual property protection for new animal varieties
can also protect the investment of biotechnological companies and accelerate the development of China's biomedicine and pharmaceutical industries.
Furthermore, trade secret law cannot provide sufficient protection for
GMOs due to their unique attributes. In addition, many countries have realized the importance of extending intellectual property protection for new
animal varieties and have enacted laws to do so.
However, a patent protection system is not economically feasible for
China. Because the initial acquisition prices and subsequent royalty fees
can be very costly, China may not be able to afford the rights to many biotechnological inventions. In particular, Chinese farmers may be deprived of
the benefits of genetically improved agricultural livestock. Instead, a narrower sui generis protection system similar to the Plant Variety Regulations
would be more appropriate.
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